236 related articles for article (PubMed ID: 32249670)
1. Predicting Antibody Developability Profiles Through Early Stage Discovery Screening.
Bailly M; Mieczkowski C; Juan V; Metwally E; Tomazela D; Baker J; Uchida M; Kofman E; Raoufi F; Motlagh S; Yu Y; Park J; Raghava S; Welsh J; Rauscher M; Raghunathan G; Hsieh M; Chen YL; Nguyen HT; Nguyen N; Cipriano D; Fayadat-Dilman L
MAbs; 2020; 12(1):1743053. PubMed ID: 32249670
[TBL] [Abstract][Full Text] [Related]
2. Molecular surface descriptors to predict antibody developability: sensitivity to parameters, structure models, and conformational sampling.
Park E; Izadi S
MAbs; 2024; 16(1):2362788. PubMed ID: 38853585
[No Abstract] [Full Text] [Related]
3. Matrixed CDR grafting: A neoclassical framework for antibody humanization and developability.
Gupta P; Horspool AM; Trivedi G; Moretti G; Datar A; Huang ZF; Chiecko J; Kenny CH; Marlow MS
J Biol Chem; 2024 Jan; 300(1):105555. PubMed ID: 38072062
[TBL] [Abstract][Full Text] [Related]
4. Deamidation and isomerization liability analysis of 131 clinical-stage antibodies.
Lu X; Nobrega RP; Lynaugh H; Jain T; Barlow K; Boland T; Sivasubramanian A; Vásquez M; Xu Y
MAbs; 2019 Jan; 11(1):45-57. PubMed ID: 30526254
[TBL] [Abstract][Full Text] [Related]
5. Sequence-developability mapping of affibody and fibronectin paratopes via library-scale variant characterization.
Nielsen GH; Schmitz ZD; Hackel BJ
Protein Eng Des Sel; 2024 Jan; 37():. PubMed ID: 38836499
[TBL] [Abstract][Full Text] [Related]
6. Nonspecificity fingerprints for clinical-stage antibodies in solution.
Herling TW; Invernizzi G; Ausserwöger H; Bjelke JR; Egebjerg T; Lund S; Lorenzen N; Knowles TPJ
Proc Natl Acad Sci U S A; 2023 Dec; 120(52):e2306700120. PubMed ID: 38109540
[TBL] [Abstract][Full Text] [Related]
7. A framework for the biophysical screening of antibody mutations targeting solvent-accessible hydrophobic and electrostatic patches for enhanced viscosity profiles.
Armstrong GB; Shah V; Sanches P; Patel M; Casey R; Jamieson C; Burley GA; Lewis W; Rattray Z
Comput Struct Biotechnol J; 2024 Dec; 23():2345-2357. PubMed ID: 38867721
[TBL] [Abstract][Full Text] [Related]
8. Affinity Maturation Enhances Antibody Specificity but Compromises Conformational Stability.
Shehata L; Maurer DP; Wec AZ; Lilov A; Champney E; Sun T; Archambault K; Burnina I; Lynaugh H; Zhi X; Xu Y; Walker LM
Cell Rep; 2019 Sep; 28(13):3300-3308.e4. PubMed ID: 31553901
[TBL] [Abstract][Full Text] [Related]
9. DOTAD: A Database of Therapeutic Antibody Developability.
Li W; Lin H; Huang Z; Xie S; Zhou Y; Gong R; Jiang Q; Xiang C; Huang J
Interdiscip Sci; 2024 Mar; ():. PubMed ID: 38530613
[TBL] [Abstract][Full Text] [Related]
10. Toward enhancement of antibody thermostability and affinity by computational design in the absence of antigen.
Hutchinson M; Ruffolo JA; Haskins N; Iannotti M; Vozza G; Pham T; Mehzabeen N; Shandilya H; Rickert K; Croasdale-Wood R; Damschroder M; Fu Y; Dippel A; Gray JJ; Kaplan G
MAbs; 2024; 16(1):2362775. PubMed ID: 38899735
[TBL] [Abstract][Full Text] [Related]
11. High-throughput developability assays enable library-scale identification of producible protein scaffold variants.
Golinski AW; Mischler KM; Laxminarayan S; Neurock NL; Fossing M; Pichman H; Martiniani S; Hackel BJ
Proc Natl Acad Sci U S A; 2021 Jun; 118(23):. PubMed ID: 34078670
[TBL] [Abstract][Full Text] [Related]
12. Designing Robust Monoclonal Antibody Drug Products: Pitfalls of Simplistic Approaches for Stability Prediction.
Rembert KB; Gokarn YR; Saluja A
J Pharm Sci; 2024 Mar; ():. PubMed ID: 38556000
[TBL] [Abstract][Full Text] [Related]
13. Understanding and overcoming trade-offs between antibody affinity, specificity, stability and solubility.
Rabia LA; Desai AA; Jhajj HS; Tessier PM
Biochem Eng J; 2018 Sep; 137():365-374. PubMed ID: 30666176
[TBL] [Abstract][Full Text] [Related]
14. The uniqueness of flow in probing the aggregation behavior of clinically relevant antibodies.
Willis LF; Kumar A; Jain T; Caffry I; Xu Y; Radford SE; Kapur N; Vásquez M; Brockwell DJ
Eng Rep; 2020 May; 2(5):e12147. PubMed ID: 34901768
[TBL] [Abstract][Full Text] [Related]
15. A method for systematically ranking therapeutic drug candidates using multiple uncertain screening criteria.
Peng X; Gibbs E; Silverman JM; Cashman NR; Plotkin SS
Stat Methods Med Res; 2021 Jun; 30(6):1502-1522. PubMed ID: 33847541
[TBL] [Abstract][Full Text] [Related]
16. Rational optimization of a monoclonal antibody improves the aggregation propensity and enhances the CMC properties along the entire pharmaceutical process chain.
Bauer J; Mathias S; Kube S; Otte K; Garidel P; Gamer M; Blech M; Fischer S; Karow-Zwick AR
MAbs; 2020; 12(1):1787121. PubMed ID: 32658605
[TBL] [Abstract][Full Text] [Related]
17. Developability assessment for monoclonal antibody drug candidates: a case study.
Garripelli VK; Wu Z; Gupta S
Pharm Dev Technol; 2021 Jan; 26(1):11-20. PubMed ID: 32986499
[TBL] [Abstract][Full Text] [Related]
18. Beyond affinity: selection of antibody variants with optimal biophysical properties and reduced immunogenicity from mammalian display libraries.
Dyson MR; Masters E; Pazeraitis D; Perera RL; Syrjanen JL; Surade S; Thorsteinson N; Parthiban K; Jones PC; Sattar M; Wozniak-Knopp G; Rueker F; Leah R; McCafferty J
MAbs; 2020; 12(1):1829335. PubMed ID: 33103593
[TBL] [Abstract][Full Text] [Related]
19. Optimization of therapeutic antibodies.
Wang B; Gallolu Kankanamalage S; Dong J; Liu Y
Antib Ther; 2021 Jan; 4(1):45-54. PubMed ID: 33928235
[TBL] [Abstract][Full Text] [Related]
20. Machine Learning for Biologics: Opportunities for Protein Engineering, Developability, and Formulation.
Narayanan H; Dingfelder F; Butté A; Lorenzen N; Sokolov M; Arosio P
Trends Pharmacol Sci; 2021 Mar; 42(3):151-165. PubMed ID: 33500170
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
